SCLXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLXW
Scilex Holding Co
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$2.57−0.26 (-9.19%)
Close on Oct 19, 2026
- Market cap
- $17.71M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
1M
Shares held, 13F filers
Institutional holders
73
12 new, 10 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 3 sales
Net sold $12.81M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| SCLX Stock Acquisition JV LLC | 30,029,378 | 11.40% | 13D (active) amendment | Jul 3, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SCLX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 301,292 | – | $2.35M | +37,242 | 0.00% |
| BlackRock, Inc. | 109,417 | – | $853.45K | +6,621 | 0.00% |
| Vanguard Fiduciary Trust Co | 45,822 | – | $357.41K | +6,164 | 0.00% |
| Jacobs Levy Equity Management, Inc | 41,163 | – | $321.07K | New | 0.00% |
| State Street Corp | 35,376 | – | $275.93K | – | 0.00% |
| UBS Group AG | 33,376 | – | $260.33K | +26,908 | 0.00% |
| Renaissance Technologies LLC | 33,064 | – | $257.90K | −3,800 | 0.00% |
| Citadel Advisors LLC | 27,497 | – | $214.48K | New | 0.00% |
| Price T Rowe Associates Inc /Md/ | 20,920 | – | $164 | New | 0.00% |
| Ashton Thomas Private Wealth, LLC | 18,482 | – | $144.16K | +493 | 0.00% |
| Northern Trust Corp | 15,047 | – | $117.37K | +14 | 0.00% |
| Morgan Stanley | 4,032 | – | $31.45K | −7,941 | 0.00% |
| Vanguard Global Advisers, LLC | 2,937 | – | $22.91K | – | 0.00% |
| Osaic Holdings, Inc. | 2,339 | – | $18.24K | +2,241 | 0.00% |
| Creative Financial Designs Inc /Adv | 1,853 | – | $14.45K | – | 0.00% |
| Jones Financial Companies Lllp | 1,755 | – | $12.48K | +1,003 | 0.00% |
| Royal Bank of Canada | 1,745 | – | $14.00K | +149 | 0.00% |
| Larson Financial Group LLC | 1,419 | – | $11.07K | +1,377 | 0.00% |
| MetLife Investment Management, LLC | 1,090 | – | $8.50K | – | 0.00% |
| Deutsche Bank AG\ | 800 | – | $6.24K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 73 | 1M | 12 / 12 | 7 / 10 | 0M | 0M |
| Q1 2026 | 73 | 1M | 7 / 8 | 15 / 11 | 0M | 0M |
| Q4 2025 | 82 | 1M | 11 / 12 | 15 / 11 | 1M | 0M |
| Q3 2025 | 83 | 1M | 24 / 13 | 15 / 9 | 0M | 0M |
| Q2 2025 | 68 | 1M | 64 / 0 | 3 / 2 | 1M | 0M |
| Q1 2025 | 6 | 0M | 6 / 0 | 0 / 1 | 0M | 0M |
| Q4 2024 | 1 | 0M | 0 / 0 | 0 / 0 | 0M | 0M |
| Q3 2024 | 1 | 0M | 0 / 0 | 0 / 0 | 0M | 0M |
| Q2 2024 | 1 | 0M | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SCLX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 217,510 | – | $1.70M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 76,230 | – | $594.59K | 0.00% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 23,935 | – | $186.69K | 0.01% | Jun 30, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 14,742 | – | $114.99K | 0.00% | Jun 30, 2026 |
| T. Rowe Price Extended Equity Market Index Fund | 6,900 | – | $53.82K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 3,805 | – | $29.68K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 3,747 | – | $29.23K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 1,683 | – | $13.13K | 0.01% | Jun 30, 2026 |
| MetLife Russell 2000 Index Portfolio | 627 | – | $4.89K | 0.00% | Jun 30, 2026 |
| Siit Extended Market Index Fund | 344 | – | $3.06K | 0.00% | May 31, 2026 |
| State Street Balanced Index Fund | 120 | – | $936 | 0.00% | Jun 30, 2026 |
| Avantis Total Equity Markets ETF | 80 | – | $712 | 0.00% | May 31, 2026 |
| Dimensional US Core Equity Market ETF | 66 | – | $440 | 0.00% | Jul 31, 2026 |
| LVIP Dimensional U.S. Core Equity 2 Fund | 39 | – | $304 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Stephen Hoi Ma | CFO, COO and Secretary, Director | 22,840 | Apr 20, 2026 |
| Henry Ji | Exec Chair, CEO and President, Director | 678,135 | Apr 20, 2026 |
| Jaisim Shah | See Remarks, Director | 295,215 | Dec 18, 2024 |
| Jay Chun | Director | 112,511 | Oct 9, 2025 |
| Dorman Followwill | Director | 2,300 | Oct 9, 2025 |
| Yue Alexander Wu | Director | 25,000 | Oct 9, 2025 |
| Stock Acquisition JV LLC SCLX | 10% owner | 958,263 | Jul 7, 2026 |
| Holding Co Scilex | 10% owner | 244,445,260 | Dec 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Stock Acquisition JV LLC SCLX 10% owner | Jul 3, 2026 | Other | −500,000 | – | – | 958,263 |
| Holding Co Scilex 10% owner | Dec 30, 2025 | Sale | −9,657,300 | $0.54 | $5.21M | 244,445,260 |
| Holding Co Scilex 10% owner | Dec 29, 2025 | Sale | −7,310,984 | $0.66 | $4.83M | 254,102,560 |
| Holding Co Scilex 10% owner | Dec 26, 2025 | Sale | −3,689,016 | $0.75 | $2.77M | 261,413,544 |
| Stock Acquisition JV LLC SCLX 10% owner | Jan 21, 2025 | Other | −3,250,000 | – | – | 51,039,214 |
| Stock Acquisition JV LLC SCLX 10% owner | Jan 16, 2025 | Other | −779,371 | – | – | 54,289,214 |
| Stock Acquisition JV LLC SCLX 10% owner | Jan 2, 2025 | Other | −5,000,000 | – | – | 55,068,585 |
| Jaisim Shah See Remarks, Director | Dec 18, 2024 | Buy | +30,000 | $0.46 | $13.80K | 139,333 |
| Henry Ji Executive Chairperson, Director | Oct 31, 2024 | Buy | +8,888 | $0.94 | $8.35K | 320,161 |
| Jaisim Shah See Remarks, Director | Oct 29, 2024 | Buy | +32,000 | $0.99 | $31.68K | 109,333 |
| Jay Chun Director | Oct 18, 2024 | Buy | +5,000 | $0.95 | $4.75K | 112,500 |
| Dorman Followwill Director | Oct 18, 2024 | Buy | +1,000 | $0.99 | $990 | 2,300 |
| David Lemus Director | Oct 17, 2024 | Buy | +2,000 | $0.90 | $1.80K | 2,000 |
| Yue Alexander Wu Director | Oct 17, 2024 | Buy | +20,000 | $0.95 | $19.00K | 25,000 |
| Henry Ji Executive Chairperson, Director | Oct 17, 2024 | Buy | +10,000 | $0.97 | $9.70K | 60,070 |
| Stephen Hoi Ma Chief Financial Officer | Oct 16, 2024 | Buy | +6,700 | $0.97 | $6.50K | 22,840 |
| Jaisim Shah See Remarks, Director | Oct 16, 2024 | Buy | +30,000 | $0.99 | $29.70K | 77,333 |
| Dorman Followwill Director | Jun 26, 2024 | Option exercise | +1,000 | $1.37 | $1.37K | 1,300 |
| Jay Chun Director | Jun 20, 2024 | Option exercise | +5,000 | $1.41 | $7.05K | 107,500 |
| Yue Alexander Wu Director | Jun 20, 2024 | Option exercise | +5,000 | $1.41 | $7.05K | 5,000 |
| Jaisim Shah See Remarks, Director | Jun 20, 2024 | Option exercise | +14,000 | $1.73 | $24.22K | 47,333 |
| Stephen Hoi Ma Chief Financial Officer | Jun 20, 2024 | Option exercise | +2,000 | $1.41 | $2.82K | 16,140 |
| Henry Ji Executive Chairperson, Director | Jun 18, 2024 | Option exercise | +6,000 | $1.41 | $8.46K | 311,273 |
| Jaisim Shah See Remarks, Director | Jun 14, 2024 | Option exercise | +33,333 | $1.41 | $47.00K | 33,333 |
| Jaisim Shah See Remarks, Director | May 17, 2024 | Buy | +56,939 | $0.92 | $52.38K | 155,882 |
| Henry Ji Executive Chairperson, Director | May 17, 2024 | Buy | +50,000 | $0.88 | $44.00K | 50,070 |
| Stephen Hoi Ma Chief Financial Officer | May 17, 2024 | Buy | +14,140 | $0.88 | $12.44K | 14,140 |
| Jay Chun Director | May 17, 2024 | Buy | +57,500 | $0.90 | $51.75K | 102,500 |
| Jaisim Shah See Remarks, Director | May 16, 2024 | Buy | +83,061 | $0.84 | $69.77K | 98,943 |
| Sorrento Therapeutics, Inc. 10% owner | Sep 21, 2023 | Sale | −60,068,585 | – | – | 1,917,210 |
| Henry Ji Executive Chairperson, Director | Mar 17, 2023 | Other | +2,730 | $8.60 | $23.48K | 2,730 |
| Sorrento Therapeutics, Inc. 10% owner | Jan 19, 2023 | Other | −73,740,795 | – | – | 61,985,795 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.